Dataset Information


Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study.

ABSTRACT: BACKGROUND:The role of antiarrhythmic drugs for atrial fibrillation/atrial flutter (AF/AFL) after catheter ablation is not well established. HYPOTHESIS:We hypothesized that changing the myocardial substrate by ablation may alter the responsiveness to dronedarone. METHODS:We assessed the efficacy and safety of dronedarone in the treatment of paroxysmal/persistent atrial fibrillation/atrial flutter (AF/AFL) post-ablation, based on a post hoc analysis of the ATHENA study. A total of 196 patients (dronedarone 90, placebo 106) had an ablation for AF/AFL before study entry. In these patients, the effect of treatment on the first hospitalization because of cardiovascular (CV) events/all-cause death was assessed, as was AF/AFL recurrence in individuals with sinus rhythm at baseline. The safety of dronedarone vs placebo was also determined. RESULTS:In patients with prior ablation, dronedarone reduced the risk of AF/AFL recurrence (hazard ratio [HR]: 0.65 [95% confidence interval [CI]: 0.42, 1.00]; P


PROVIDER: S-EPMC7068068 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7724236 | BioStudies
1000-01-01 | S-EPMC3961599 | BioStudies
2020-01-01 | S-EPMC7318600 | BioStudies
2014-01-01 | S-EPMC6647669 | BioStudies
2021-01-01 | S-EPMC7779821 | BioStudies
1000-01-01 | S-EPMC4753968 | BioStudies
2015-01-01 | S-EPMC4441372 | BioStudies
1000-01-01 | S-EPMC4101193 | BioStudies
2019-01-01 | S-EPMC6486838 | BioStudies
2015-01-01 | S-EPMC4346668 | BioStudies